HOPE Therapeutics is a daughter company of NRx Pharmaceuticals. We are led by a veteran team of health and biotech innovators who began a mission in 2015 to cure suicidal depression.
Today, HOPE is an independently operated company leveraging our clinical and scientific expertise to provide a comprehensive care path to people struggling with mental health and cognitive disorders.
Dr Javitt is a business and thought leader in healthcare, biotech, health informatics, and public policy. He is Founder, Chairman, and CEO of NRx Pharmaceuticals (Nasdaq:NRXP) the parent company of HOPE Therapeutics that is developing the first FDA-approved treatments for suicidal depression and PTSD.
Jonathan has been a founder in 7 health informatics and analytics companies that reached successful public exits: Healthcare Computer Associates (NYSE: SMSI), NextGen (Nasdaq:QSII), Certitude (NYSE:UNH), Active Health Management (NYSE:UNH), First Gateways (NYSE:DGX), Coderyte, Inc., (NYSE:3M), and Telcare, Inc. (Nasdaq:BEAT) which was funded by Qualcomm Ventures, Sequoia Capital, and Venture Partners.
In the policy arena, Prof. Javitt has served as a senior health advisor to four US Presidential administrations, starting as an Expert Consultant to the Medicare Program under Presidents Reagan and Bush ’41. Subsequently, he was appointed a Special Government Employee to the White House Executive Office of the President under President Clinton. He was commissioned by President George W. Bush ’43 to support the Undersecretary of Defense (ATL) and subsequently to chair the Health Subcommittee of the President’s Information Technology Advisory Committee (PITAC) which created the blueprint for the Office of the National Coordinator for Health IT and the HITECH act.
Dr. Javitt brings direct experience related to the challenges of severe depression and PTSD in the civilian, military and first responder communities. He is a Flotilla Commander in the US Coast Guard Auxiliary, a Branch Chief on its National Staff. As an aviator in the Air Auxiliary, he regularly flies search and rescue missions. He is able to represent the policy agenda of DHS Leadership, while speaking the language of First Responders, having been one since the age of 20.
Jonathan is an alumnus of Princeton University, Weill Cornell Medical College, the Harvard School of Public Health which has recognized him as an Alumnus of Merit, and the Johns Hopkins University School of Medicine, where he continues to serve as an Adjunct Professor. His scientific works have been cited by more than 36,000 authors worldwide and he is among the top 1% of published scientists.
Dr Cohen is an Interventional Psychiatrist and Psychopharmacologist specializing in the treatment of mood and anxiety disorders as well as a nationally recognized expert in Transcranial Magnetic Stimulation (TMS). Cohen & Associates, was established in 2014 as one of the nation’s firs interventional psychiatry practices. Dr Cohen brings pivotal leadership and clinical expertise to the entire HOPE network, defining and instilling HOPE’s clinical values and focus on comprehensive, neuroplastic care.
Dr Cohen is a graduate of Tufts University and Boston University, where she earned her MS In medical sciences and was awarded her MD together with the psychiatry department’s Malamud Award for Excellence. She trained In adult psychiatry training at the University of Minnesota and Georgetown University, where she was twice awarded the Hugh H. Hussey Teaching award. She completed her fellowship in psychotherapy at the Boston Psychoanalytic Society and Institute. She was appointed a Site Investigator of the National Outcomes Study for TMS in 2012.
She currently serves on the International Clinical TMS Society (CTMSS) Board of Directors and has served as the Co-Chair of the Society’s Membership Committee.
Stephen, a US Army Reserve veteran, attended Wolford College where he received his training as a Certified Registered Nurse Anesthetist (CRNA) and earned a Master’s degree from Florida Gulf Coast University. After specializing in obstetric (OB) anesthesia, Stephen became a clinical instructor and professor, training hundreds of anesthesia students over a 15 year span.
When ketamine was first discovered to be effective in treating mood and pain disorders, Stephen engaged in an extensive training course in the use of Ketamine to treat depression, suicidal ideation, anxiety, PTSD, OCD and chronic pain. Together with his wife Liz Durand, RN, he founded Dura Medical in 2018 with the mission to treat 10,000 patients with suicidal depression.
Stephen joined HOPE Therapeutics in 2025 as Director of Florida Clinic Operations and leads a rapidly expanding network of HOPE interventional psychiatry clinics, helping them fulfill Hope’s clinical values statewide.
Michael Abrams serves as CFO of NRx Pharmaceuticals (NASDAQ: NRXP), parent company of HOPE Therapeutics, and as CFO of HOPE.
Mr Abrams is a senior finance professional with almost three decades of experience as an executive officer, investment banker, director and senior advisor; including as the Chief Financial Officer of Arch Therapeutics, RiseIT Solutions, and FitLife Brands. Mr. Abrams has deep experience across multiple functional areas including, but not limited to, financial operations, accounting, mergers and acquisitions, financial engineering, capital raising and shareholder communications. He earned his MBA with Honors from the University of Chicago Booth School of Business following his BBA with Honors from the University of Massachusetts at Amherst, where he was named a William F. Field alumni scholar.
HOPE Therapeutics / NRx Pharmaceuticals is committed to protecting and respecting your privacy, and we’ll only use your personal information to contact you if you subscribe to our newsletter. You can unsubscribe from these communications at any time. For more information on how to unsubscribe, our privacy practices, and our commitment to protecting and respecting your privacy, please review our Privacy Policy. By clicking submit below, you consent to allow HOPE Therapeutics / NRx Pharmaceuticals to store and process the personal information submitted above to provide you with the content requested.
Effective Date: Jan 1st, 2026
1. Program Description: This messaging program sends appointment confirmation and reminder messages to customers who have booked an appointment with Hope Therapeutics through our website at https://hopetherapeutics.com/, or via our scheduling forms, and have explicitly opted in to receive SMS notifications. Opt-in is collected via web forms with a dedicated checkbox for SMS consent. Messages include scheduling confirmations, appointment reminders, rescheduling updates, and customer support communications.
2. Cancellation Instructions: You can cancel the SMS service at any time. Simply text “STOP” to the same number that sent you messages. Upon sending “STOP,” we will confirm your unsubscribe status via SMS. Following this confirmation, you will no longer receive SMS messages from us. To rejoin, sign up as you did initially, and we will resume sending SMS messages to you.
3. Support Information: If you experience issues with the messaging program, reply with the keyword “HELP” for more assistance, or reach out directly to team@hopetherapeutics.com or call 833-446-7386 during business hours.
4. Carrier Liability: Carriers are not liable for delayed or undelivered messages.
5. Message & Data Rates: Message and data rates may apply for messages sent to you from us and to us from you. Message frequency varies based on your service usage and appointment schedule. For questions about your text plan or data plan, contact your wireless provider.
6. Supported Carriers: Our SMS program works with all major U.S. wireless carriers, including AT&T, T-Mobile, Verizon, Sprint, and most regional carriers.
7. Age Restriction: You must be 18 years or older to participate in our SMS program.
8. Privacy Policy: For privacy-related inquiries, please refer to our Privacy Policy at https://hopetherapeutics.com/privacy-policy
We comply with all applicable laws and regulations, including the Telephone Consumer Protection Act (TCPA) and CTIA guidelines, regarding the use of SMS communications.
This website (the “Site”) is owned and operated by Hope Therapeutics (“COMPANY,” “we” or “us”). By using the Site, you agree to be bound by these Terms of Service and to use the Site in accordance with these Terms of Service, our Privacy Policy, and any additional terms and conditions that may apply to specific sections of the Site or to products and services available through the Site or from Hope Therapeutics.
Accessing the Site, in any manner, whether automated or otherwise, constitutes use of the Site and your agreement to be bound by these Terms of Service.
We reserve the right to change these Terms of Service or to impose new conditions on the use of the Site from time to time, in which case we will post the revised Terms of Service on this website. By continuing to use the Site after we post any such changes, you accept the Terms of Service, as modified.
This Site and all the materials available on the Site are the property of Hope Therapeutics and/or our affiliates or licensors and are protected by copyright, trademark, and other intellectual property laws. The Site is provided solely for your personal non-commercial use.
You may not use the Site or the materials available on the Site in a manner that constitutes an infringement of our rights or that has not been authorized by us.
Unless explicitly authorized, you may not modify, copy, reproduce, republish, upload, post, transmit, translate, sell, create derivative works, exploit, or distribute in any manner or medium any material from the Site. However, you may download and/or print one copy of individual pages for your personal, non-commercial use, provided that you keep intact all copyright and other proprietary notices.
By posting or submitting any material (including comments, blog entries, social media posts, photos, and videos) to us via the Site, internet groups, or other digital venues, you represent that you own the material or have obtained the necessary permissions. You grant us a royalty-free, perpetual, irrevocable, non-exclusive, worldwide license to use, modify, transmit, sell, exploit, create derivative works from, distribute, and publicly perform or display such material.
Throughout the Site, we may provide links and pointers to Internet sites maintained by third parties. Our linking to such third-party sites does not imply an endorsement or sponsorship of such sites or the information, products, or services offered on or through the sites.
The information, products, and services offered on or through the Site are provided “as is” and without warranties of any kind, either express or implied. To the fullest extent permissible pursuant to applicable law, we disclaim all warranties, including implied warranties of merchantability and fitness for a particular purpose.
You agree at all times to indemnify and hold harmless Hope Therapeutics, its affiliates, and their respective officers, directors, agents, and employees from any claims, causes of action, damages, liabilities, costs, and expenses arising out of or related to your breach of any obligation, warranty, or representation under these Terms of Service.
Certain sections of the Site may allow you to purchase products and services from third-party vendors. We are not responsible for the quality, accuracy, timeliness, reliability, or any other aspect of these products and services. If you make a purchase from a third party linked through the Site, the information obtained during your visit, including payment information, may be collected by both the merchant and us.
Your participation in any dealings with third-party vendors is solely between you and the third party. Hope Therapeutics shall not be responsible for any loss or damage incurred as a result of such dealings.
To access certain features of the Site, you may be required to register and create an account. You agree to provide accurate, current, and complete information during the registration process. You are responsible for maintaining the confidentiality of your login credentials and for all activities conducted under your account.
If you suspect unauthorized use of your account, notify us immediately at team@hopetherapeutics.com. We are not liable for any loss or damage arising from your failure to comply with this obligation.
We reserve the right to terminate or suspend your access to the Site, without notice, if we determine that you have violated these Terms of Service or engaged in conduct that we deem inappropriate or unlawful. Upon termination, you must cease all use of the Site and any content obtained from it.
These Terms of Service shall be governed by and construed in accordance with the laws of the state of Florida. Any dispute arising under these Terms shall be resolved exclusively through binding arbitration in that jurisdiction.
We may update these Terms of Service from time to time. The latest version will always be available on our website with the effective date.
For any questions regarding these Terms of Service, please contact us at:
Hope Therapeutics
Phone: 833-446-7386
Email: team@hopetherapeutics.com
Website: https://hopetherapeutics.com/
By using our website and services, you consent to these Terms of Service.
Effective Date: Jan 1st, 2026
IMPORTANT NOTICE REGARDING TEXT MESSAGING
DATA
Hope Therapeutics (“we,” “us,” or “our”) DOES NOT share customer opt-in information, including phone numbers and consent records, with any affiliates or third parties for marketing, promotional, or any other purposes unrelated to providing our direct services. All text messaging originator opt-in data is kept strictly confidential.
We collect the following types of information:
We use collected data for:
By opting into our SMS messaging services, you agree to receive text messages related to our services, including appointment reminders, customer support, and important updates.
No mobile information will be shared with third parties/affiliates for marketing/promotional purposes. Information sharing to subcontractors in support services, such as customer service is permitted. All other use case categories exclude text messaging originator opt-in data and consent; this information will not be shared with any third parties.
We implement strict data protection measures to safeguard your SMS opt-in information and consent records.
We do not sell, rent, or trade personal information. We may share information with:
All the above categories exclude text messaging originator opt-in data and consent; this information will not be shared with any third parties, excluding aggregators and providers of the Text Message services.
We implement and maintain reasonable security measures to protect your personal information:
Despite these measures, no method of transmission over the Internet or electronic storage is 100% secure. We strive to use commercially acceptable means to protect your personal information but cannot guarantee absolute security.
We use cookies and similar technologies to:
You may control cookies through your browser settings. Disabling cookies may limit your ability to use certain features of our website.
You have the right to:
To exercise these rights, please contact us using the information in Section 10.
Our website may contain links to third-party websites. We are not responsible for their privacy practices and encourage you to review their policies. This privacy policy applies only to information collected by Hope Therapeutics.
We may update this policy periodically. The latest version will always be available on our website with the effective date. For significant changes, we will notify you by email or through a notice on our website.
If you have questions about this Privacy Policy or how your information is handled, contact us at:
Hope Therapeutics
Phone: 833-446-7386
Email: team@hopetherapeutics.com
Website: https://hopetherapeutics.com/
By using our website and services, you consent to this Privacy Policy.